SGTB Inhibitors

The compounds classified as SGTB inhibitors represent a diverse group of chemicals that, while not directly targeting SGTB, can potentially influence the cellular processes and pathways where SGTB might play a role. Roscovitine, for example, targets cyclin-dependent kinases, which play pivotal roles in cell cycle regulation. By altering cell cycle dynamics, it can indirectly affect proteins like SGTB that might have cell cycle-related roles.

The cellular proteostasis, or protein homeostasis, is another crucial domain that involves a balance between protein synthesis and degradation. Cycloheximide, a protein synthesis inhibitor, and MG132, a proteasome inhibitor, represent two agents that tilt this balance. Their actions could result in altered SGTB protein levels, given the delicate equilibrium of protein synthesis and degradation. Furthermore, cellular signaling, modulated by factors like growth factors and calcium, remains integral to numerous cellular decisions. Compounds like PD173074, which targets FGF receptors, and KN-93, a CaMKII inhibitor, can potentially alter these signaling cascades, leading to indirect effects on proteins like SGTB that might be downstream effectors or have related functions.